Inovio Pharmaceuticals (INO) Competitors

$1.18 -0.01 (-0.84%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.00 (+0.34%)

As of 07/10/2026 06:33 PM Eastern

INO vs. MRNA, ELMD, CARL, SGHT, and TLSI

Should you buy Inovio Pharmaceuticals stock or one of its competitors? MarketBeat compares Inovio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inovio Pharmaceuticals include Moderna (MRNA), Electromed (ELMD), Carlsmed (CARL), Sight Sciences (SGHT), and TriSalus Life Sciences (TLSI).

How does Inovio Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Moderna had 22 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 23 mentions for Moderna and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.89 beat Moderna's score of 0.72 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Moderna	Positive
Inovio Pharmaceuticals	Very Positive

Moderna presently has a consensus target price of $38.27, indicating a potential downside of 43.95%. Inovio Pharmaceuticals has a consensus target price of $4.25, indicating a potential upside of 260.17%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Inovio Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.93	-$2.82B	-$8.15	N/A
Inovio Pharmaceuticals	$60K	1,617.98	-$84.95M	-$1.45	N/A

75.3% of Moderna shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Summary

Inovio Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Electromed?

Inovio Pharmaceuticals (NASDAQ:INO) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Electromed. MarketBeat recorded 1 mentions for Inovio Pharmaceuticals and 0 mentions for Electromed. Inovio Pharmaceuticals' average media sentiment score of 1.89 beat Electromed's score of 1.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Very Positive
Electromed	Positive

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to Inovio Pharmaceuticals' net margin of 0.00%. Electromed's return on equity of 15.71% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Electromed	11.34%	15.71%	13.37%

Inovio Pharmaceuticals presently has a consensus price target of $4.25, indicating a potential upside of 260.17%. Electromed has a consensus price target of $37.50, indicating a potential downside of 17.85%. Given Inovio Pharmaceuticals' higher probable upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Electromed has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,617.98	-$84.95M	-$1.45	N/A
Electromed	$71.75M	5.27	$5.15M	$1.17	39.02

Inovio Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

Electromed beats Inovio Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Carlsmed presently has a consensus price target of $18.75, indicating a potential upside of 57.56%. Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 260.17%. Given Inovio Pharmaceuticals' higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Carlsmed had 1 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 2 mentions for Carlsmed and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.89 beat Carlsmed's score of 0.94 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Carlsmed	Positive
Inovio Pharmaceuticals	Very Positive

Carlsmed has higher revenue and earnings than Inovio Pharmaceuticals. Carlsmed is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	6.40	-$29.63M	-$2.51	N/A
Inovio Pharmaceuticals	$60K	1,617.98	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Summary

Inovio Pharmaceuticals beats Carlsmed on 7 of the 13 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sight Sciences had 12 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 13 mentions for Sight Sciences and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.89 beat Sight Sciences' score of -0.14 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Sight Sciences	Neutral
Inovio Pharmaceuticals	Very Positive

Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals. Sight Sciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.74	-$38.43M	-$0.71	N/A
Inovio Pharmaceuticals	$60K	1,617.98	-$84.95M	-$1.45	N/A

Sight Sciences presently has a consensus price target of $8.25, indicating a potential upside of 55.08%. Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 260.17%. Given Inovio Pharmaceuticals' higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Sight Sciences beats Inovio Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Inovio Pharmaceuticals (NASDAQ:INO) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 1.89 equaled TriSalus Life Sciences'average media sentiment score.

Company	Overall Sentiment
Inovio Pharmaceuticals	Very Positive
TriSalus Life Sciences	Very Positive

Inovio Pharmaceuticals currently has a consensus target price of $4.25, suggesting a potential upside of 260.17%. TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 81.16%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

TriSalus Life Sciences has higher revenue and earnings than Inovio Pharmaceuticals. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,617.98	-$84.95M	-$1.45	N/A
TriSalus Life Sciences	$45.15M	5.63	-$39.23M	-$1.41	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

Summary

Inovio Pharmaceuticals beats TriSalus Life Sciences on 7 of the 13 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$97.08M	$3.76B	$7.13B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-0.81	21.83	27.42	24.58
Price / Sales	1,617.98	323.85	592.92	122.65
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	3.28	8.41	10.88	6.38
Net Income	-$84.95M	$23.85M	$3.59B	$331.87M
7 Day Performance	-3.28%	-0.75%	-0.26%	0.37%
1 Month Performance	7.27%	8.81%	4.51%	0.53%
1 Year Performance	-13.24%	53.66%	29.17%	21.96%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	2.8454 of 5 stars	$1.18 -0.8%	$4.25 +260.2%	-15.1%	$97.08M	$60K	N/A	320	Positive News
MRNA Moderna	1.8767 of 5 stars	$69.77 +3.7%	$37.13 -46.8%	+99.2%	$27.40B	$1.94B	N/A	4,700	Trending News Analyst Forecast Options Volume
ELMD Electromed	1.2904 of 5 stars	$41.31 -0.4%	$37.50 -9.2%	+128.1%	$339.94M	$71.75M	54.74	160	News Coverage Positive News
CARL Carlsmed	2.9718 of 5 stars	$11.54 -1.9%	$19.33 +67.5%	N/A	$312.30M	$50.51M	N/A	100	News Coverage Positive News
SGHT Sight Sciences	3.5505 of 5 stars	$5.57 -2.2%	$8.14 +46.3%	+55.1%	$300.51M	$77.36M	N/A	210	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ELMD, CARL, SGHT, and TLSI

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Summary

How does Inovio Pharmaceuticals compare to Sight Sciences?

Summary

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ELMD, CARL, SGHT, and TLSI

How does Inovio Pharmaceuticals compare to Moderna?

Does the media refer more to MRNA or INO?

Do analysts prefer MRNA or INO?

Which has higher earnings & valuation, MRNA or INO?

Do institutionals and insiders believe in MRNA or INO?

Which has more volatility & risk, MRNA or INO?

Is MRNA or INO more profitable?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Does the media prefer INO or ELMD?

Do institutionals and insiders have more ownership in INO or ELMD?

Is INO or ELMD more profitable?

Do analysts prefer INO or ELMD?

Which has stronger earnings & valuation, INO or ELMD?

Which has more volatility & risk, INO or ELMD?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Do insiders & institutionals have more ownership in CARL or INO?

Do analysts rate CARL or INO?

Does the media favor CARL or INO?

Which has preferable earnings & valuation, CARL or INO?

Is CARL or INO more profitable?

Summary

How does Inovio Pharmaceuticals compare to Sight Sciences?

Is SGHT or INO more profitable?

Which has more volatility & risk, SGHT or INO?

Do insiders and institutionals believe in SGHT or INO?

Does the media refer more to SGHT or INO?

Which has better earnings and valuation, SGHT or INO?

Do analysts prefer SGHT or INO?

Summary

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Do insiders & institutionals hold more shares of INO or TLSI?

Does the media prefer INO or TLSI?

Do analysts recommend INO or TLSI?

Which has more volatility & risk, INO or TLSI?

Which has stronger earnings & valuation, INO or TLSI?

Is INO or TLSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools